Dermatology and Ortho Practices Are Piloting AI Verification Tools to Cut Prior-Auth Backlogs

Insurance verification has long been a staffing drain in high-volume specialty practices. In dermatology, where a single provider may bill for a procedure, a pathology read, and a modifier-laden destruction code on the same visit, verification errors compound quickly. In orthopedics, prior authorizations for imaging and surgical implants routinely stall scheduling by days. Now a growing number of mid-size specialty groups are piloting AI-assisted revenue cycle management tools specifically to address those friction points — and early adopters are reporting tangible, if uneven, results.

The pressure to automate is partly administrative and partly financial. The American Medical Association's 2023 prior authorization survey found that 94 percent of physicians reported care delays tied to prior-auth requirements, and 80 percent said the process led to treatment abandonment in at least some cases. Those figures carry particular weight in dermatology, where biologics for moderate-to-severe psoriasis or atopic dermatitis carry list prices that payers scrutinize closely, and in orthopedics, where implant-cost disputes between practices and insurers are common. For more on the topic discussed above, see Medical Practice Press.

What the Tools Actually Do — and Where They Fall Short

Most of the AI-assisted verification platforms being tested in specialty settings work by pulling eligibility data from payer APIs or clearinghouses, cross-referencing it against procedure codes, and flagging likely denial risks before claims are submitted. Some layer on prior-auth initiation, sending structured clinical documentation to payers automatically based on templated rules. Companies including Waystar and Availity have expanded their specialty-focused modules in the past 18 months, and several EHR vendors have introduced native RCM automation within their dermatology and orthopedic workflow editions.

The practical limitation that practices report most consistently is payer-specific variability. A tool calibrated on commercial plan logic may misfire on Medicare Advantage plans, which each set their own prior-auth lists under CMS guidelines. The Centers for Medicare and Medicaid Services finalized a rule in January 2024 requiring Medicare Advantage organizations to respond to standard prior-auth requests within 7 calendar days and urgent requests within 72 hours — a change that affects how practices should configure their automation timelines. Tools that do not account for plan-type distinctions generate false confidence and can accelerate denials rather than prevent them.

Staffing context matters too. Smaller dermatology practices with one or two billers often find that automation shifts rather than eliminates labor. Someone still needs to review exception queues, manage appeal workflows, and update clinical templates when payer policies change. The practices that report the clearest efficiency gains tend to have a dedicated RCM coordinator who owns the tool configuration, not a front-desk employee who inherited the software alongside other duties.

For specialty practice administrators evaluating these platforms, the most useful due diligence step is requesting denial-rate data segmented by payer type and CPT code range — not blended averages. Vendors willing to share that specificity are demonstrating that their tools have been stress-tested against the payer mix that actually matters in dermatology and orthopedics. Those who offer only top-line denial-reduction claims deserve closer scrutiny before any contract is signed.